Abattis Bioceuticals Corp (CNSX:ATT) Director William Panenka sold 90,000 shares of the firm’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of C$0.53, for a total value of C$47,700.00.

William Panenka also recently made the following trade(s):

  • On Tuesday, January 16th, William Panenka sold 25,000 shares of Abattis Bioceuticals stock. The stock was sold at an average price of C$0.67, for a total value of C$16,750.00.
  • On Tuesday, December 12th, William Panenka sold 100,000 shares of Abattis Bioceuticals stock. The stock was sold at an average price of C$0.48, for a total value of C$48,000.00.

Abattis Bioceuticals Corp (CNSX ATT) traded up C$0.01 during trading on Friday, reaching C$0.61. The company had a trading volume of 1,710,000 shares, compared to its average volume of 2,970,000. The firm has a market capitalization of $136.43 and a price-to-earnings ratio of -15.25. Abattis Bioceuticals Corp has a 12-month low of C$0.05 and a 12-month high of C$0.74.

COPYRIGHT VIOLATION NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2018/01/19/abattis-bioceuticals-corp-att-director-sells-c47700-00-in-stock.html.

About Abattis Bioceuticals

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets.

Receive News & Ratings for Abattis Bioceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abattis Bioceuticals and related companies with MarketBeat.com's FREE daily email newsletter.